Liberty Hospital chief medical officer receives highest honor in field of infectious diseases newspressnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newspressnow.com Daily Mail and Mail on Sunday newspapers.
4 Min Read
(Reuters) - U.S. hospitals have been slow to embrace COVID-19 antibody drugs from Eli Lilly and Co and Regeneron Pharmaceuticals Inc that have been authorized to reduce the risk of hospitalization, U.S. officials said on Wednesday.
Slideshow ( 2 images )
Demand for the therapies, which are given as a one-time intravenous infusion, has been “disappointing,” and hospitals should be using them more, Operation Warp Speed chief advisor Dr. Moncef Slaoui said on a conference call. The government program is distributing and allocating the drugs.
Healthcare systems say they have been slow to ramp up use of the antibodies due to extra levels of complexity during the pandemic - including requirements for quick diagnosis times and the need to isolate infectious patients.
Understanding the Different Coronavirus Tests yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
By Deena Beasley
Dec 16 (Reuters) - U.S. hospitals have been slow to embrace COVID-19 antibody drugs from Eli Lilly and Co and Regeneron Pharmaceuticals Inc that have been authorized to reduce the risk of hospitalization, U.S. officials said on Wednesday.
Demand for the therapies, which are given as a one-time intravenous infusion, has been disappointing, and hospitals should be using them more, Operation Warp Speed chief advisor Dr. Moncef Slaoui said on a conference call. The government program is distributing and allocating the drugs.
Healthcare systems say they have been slow to ramp up use of the antibodies due to extra levels of complexity during the pandemic - including requirements for quick diagnosis times and the need to isolate infectious patients.
Search jobs Clinical Microbiology Market Size worth $3.98 Billion | Global Industry Analysis and Opportunity Assessment 2020-2026
Pune, Maharashtra, India, December 16 2020 (Wiredrelease) Brandessence Market Research and Consulting Pvt ltd –:Clinical Microbiology Market is valued at USD 2.60 Billion in 2018 and expected to reach USD 3.98 Billion by 2025 with CAGR of 6.26% over the forecast period.
Market Analysis of Clinical Microbiology-
Clinical microbiology is often performing in the laboratories that includes the analysis of different group of microorganisms. Clinical microbiology laboratories perform aerobic and anaerobic bacteriology, parasitology, mycology, virology and etc. This testing procedure focuses on the isolation and characterization of infectious organisms to treat the patients timely. It plays an important role in diagnosis and management of patients with lower respiratory tract infections. In clinical microbiology laboratories, trad